RESUMO
BACKGROUND AND PURPOSE: Asthma exacerbations contribute to corticosteroid insensitivity. LPS is ubiquitous in the environment. It causes bronchoconstriction and airway inflammation and may therefore exacerbate allergen responses. This study examined whether LPS and ovalbumin co-administration could exacerbate the airway inflammatory and functional responses to ovalbumin in conscious guinea pigs and whether these exacerbated responses were insensitive to inhaled corticosteroid treatment with fluticasone propionate (FP). EXPERIMENTAL APPROACH: Guinea pigs were sensitized and challenged with ovalbumin and airway function recorded as specific airway conductance by whole body plethysmography. Airway inflammation was measured from lung histology and bronchoalveolar lavage. Airway hyper-reactivity (AHR) to inhaled histamine was examined 24 h after ovalbumin. LPS was inhaled alone or 24 or 48 h before ovalbumin and combined with ovalbumin. FP (0.05-1 mg·mL(-1) ) or vehicle was nebulized for 15 min twice daily for 6 days before ovalbumin or LPS exposure. KEY RESULTS: Ovalbumin inhalation caused early (EAR) and late asthmatic response (LAR), airway hyper-reactivity to histamine and influx of inflammatory cells into the lungs. LPS 48 h before and co-administered with ovalbumin exacerbated the response with increased length of the EAR, prolonged response to histamine and elevated inflammatory cells. FP 0.5 and 1 mg·mL(-1) reduced the LAR, AHR and cell influx with ovalbumin alone, but was ineffective when guinea pigs were exposed to LPS before and with ovalbumin. CONCLUSIONS AND IMPLICATIONS: LPS exposure exacerbates airway inflammatory and functional responses to allergen inhalation and decreases corticosteroid sensitivity. Its widespread presence in the environment could contribute to asthma exacerbations and corticosteroid insensitivity in humans.
Assuntos
Asma/tratamento farmacológico , Fluticasona/administração & dosagem , Fluticasona/farmacologia , Inflamação/tratamento farmacológico , Lipopolissacarídeos/efeitos adversos , Lipopolissacarídeos/imunologia , Ovalbumina/imunologia , Administração por Inalação , Animais , Asma/induzido quimicamente , Asma/imunologia , Hiper-Reatividade Brônquica/induzido quimicamente , Hiper-Reatividade Brônquica/tratamento farmacológico , Líquido da Lavagem Broncoalveolar/citologia , Modelos Animais de Doenças , Resistência a Medicamentos/efeitos dos fármacos , Fluticasona/uso terapêutico , Cobaias , Histamina/efeitos adversos , Inflamação/induzido quimicamente , Pulmão/efeitos dos fármacos , Pulmão/patologia , Masculino , Pletismografia TotalRESUMO
House dust mite (HDM) is the major source of allergen in house dust and is strongly associated with the development of asthma. HDM can evoke a direct, nonallergic inflammatory reaction in vitro. We aimed to determine whether this apparent nonallergic, inflammatory response can be observed in a more complex in vivo setting. Vehicle, Alum or HDM (Dermatophagoides pteronyssinus 5 microg, i.p. with Alum) sensitised Brown-Norway rats were challenged intratracheally with vehicle (saline), HDM (Der p 10 microg) or heat-inactivated HDM on day 21. Lung function changes and the associated inflammatory response were evaluated. Tissue and bronchoalveolar lavage from Alum sensitised Der p challenged animals exhibited strong eosinophilia and neutrophilia associated with an early release of pro-inflammatory cytokines (interleukin-13 and 1beta, eotaxin and thymus and activation-regulated chemokine). This response was not attenuated by removal of HDM-associated protease activity. Interestingly, the vehicle sensitised group (no Alum) lacked this inflammatory response. HDM allergen evokes nonallergic airways inflammation with an inflammatory profile similar to that of the asthmatic airway. This response, independent of the protease activity of the HDM extract, appeared to be linked to prior administration of the adjuvant Alum and the subsequent increase in total immunoglobulin E. This finding could have important implications in the development of future asthma therapies.
Assuntos
Antígenos de Dermatophagoides/imunologia , Asma/imunologia , Pneumonia/imunologia , Pyroglyphidae/imunologia , Resistência das Vias Respiratórias/imunologia , Compostos de Alúmen/farmacologia , Animais , Asma/terapia , Líquido da Lavagem Broncoalveolar/imunologia , Broncoconstrição/imunologia , Quimiocinas/genética , Quimiocinas/imunologia , Citocinas/genética , Citocinas/imunologia , Modelos Animais de Doenças , Imunoglobulina E/sangue , Pulmão/imunologia , Masculino , Pneumonia/terapia , RNA Mensageiro/metabolismo , Ratos , Ratos Endogâmicos BN , Baço/imunologiaRESUMO
OBJECTIVE AND DESIGN: The aim was to determine the time courses for the changes in airway function, airway reactivity, influx of inflammatory cells and levels of the pro-inflammatory cytokines, interleukin (IL)-5 and IL-8 in bronchoalveolar lavage fluid (BALF), and the plasma levels of cortisol and ACTH after antigen challenge to determine whether a temporal link could be established between these events. METHODS: Airway function was measured as specific airway conductance (sGsw) in conscious ovalbumin (OvA)-sensitized guinea pigs using whole body plethysmography at intervals after an inhalation challenge with ovalbumin (0.5% for 10 min). Airway responses to the inhaled spasmogen, U46619 (30 ng/ml, 60 s), were measured at 3, 6 and 24 h after challenge. In separate animals, bronchoalveolar lavage fluid (BALF) was obtained after anaesthetic overdose either before challenge or at 1, 3, 6, 12, or 24 h after OvA challenge. Total and differential cell counts of eosinophils and neutrophils were performed on BALF and levels of IL-5 and IL-8 determined by scintillation proximity assays and ELISA, respectively. Plasma cortisol and ACTH levels were determined by RIA kits in blood removed by cardiac puncture at intervals after challenge. RESULTS: An early phase bronchoconstriction occurred which resolved by 3 h and was followed by a late phase between 17 and 24 h. Airway hyperresponsiveness to inhaled U46619, was evident at 3, 6 and 24 h after antigen challenge. Increased IL-5[BALF] was observed by 60 min post challenge implicating a performed storage site. In contrast, IL-8[BALF] was not raised until 3 h post challenge. There was a significant infiltration of neutrophils and eosinophils by 3 and 6 h, respectively. IL-5[BALF] further increased up to 24 h, during the appearance of the late phase of bronchoconstriction and whilst eosinophilia was maximal. Plasma cortisol levels were increased 1 and 3 hours after antigen challenge, thereafter returning to baseline levels. CONCLUSIONS: The hyperresponsiveness appears to be dissociated from the appearance of eosinophils in lavage fluid. The early appearance of IL-5, however, could be a trigger for the migration of eosinophils and development of hyper-responsiveness. The increased plasma cortisol levels occurring after antigen challenge were presumably due to the stress involved and these would be expected to exert an endogenous anti-inflammatory effect.
Assuntos
Hiper-Reatividade Brônquica/metabolismo , Hiper-Reatividade Brônquica/patologia , Citocinas/metabolismo , Hidrocortisona/sangue , Leucócitos/patologia , Pulmão/metabolismo , Ácido 15-Hidroxi-11 alfa,9 alfa-(epoximetano)prosta-5,13-dienoico/farmacologia , Hormônio Adrenocorticotrópico/sangue , Resistência das Vias Respiratórias , Animais , Hiper-Reatividade Brônquica/imunologia , Hiper-Reatividade Brônquica/fisiopatologia , Líquido da Lavagem Broncoalveolar/citologia , Broncoconstrição/efeitos dos fármacos , Cobaias , Técnicas In Vitro , Interleucina-5/metabolismo , Interleucina-8/metabolismo , Leucócitos/metabolismo , Pulmão/patologia , Masculino , Ovalbumina/toxicidade , Pletismografia Total , Fatores de TempoRESUMO
This article describes the development and validation of a scintillation proximity assay (SPA) sensitive for guinea-pig interleukin-5 (IL-5). SPA beads were coated with TRFK-5, a monoclonal antibody directed against mouse IL-5, which is known also to bind guinea-pig IL-5. The assay is a simple competitive binding assay between [125I]-rh-IL-5 and the IL-5, in a sample of guinea-pig bronchoalveolar lavage fluid (BALF), for the binding site on the TRFK-5-coated beads. IL-5 levels in BALF ([IL-5]BALF) were shown to increase in guinea-pigs sensitized to ovalbumin (OvA) and challenged with an OvA inhalation. This occurred at a time (24 h) after challenge when there was also a marked eosinophilia. The assay was validated by treating guinea-pigs with a second antibody, Genzyme 2374-01, directed against IL-5. Treatment with this antibody resulted in a significant reduction of the antigen-induced eosinophilia and concentration of [IL-5]BALF. This observation confirms that the IL-5 identified in BALF also cross-reacts with the antibody Genzyme 2374-01. Interestingly, plasma from sensitized, but unchallenged, guinea-pigs also contained detectable levels of IL-5, and the stimulation of plasma protein extravasation (PPE) within the airways with inhaled histamine also induced a rise in [IL-5]BALF. These observations suggest that the plasma may be an additional source of the IL-5 present in the airways of antigen-challenged guinea-pigs.
Assuntos
Líquido da Lavagem Broncoalveolar/química , Interleucina-5/análise , Administração por Inalação , Animais , Anticorpos Monoclonais/metabolismo , Anticorpos Monoclonais/farmacologia , Anticorpos Monoclonais/uso terapêutico , Formação de Anticorpos , Ligação Competitiva , Proteínas Sanguíneas/metabolismo , Líquido da Lavagem Broncoalveolar/citologia , Eosinofilia/induzido quimicamente , Eosinofilia/tratamento farmacológico , Cobaias , Histamina/administração & dosagem , Histamina/imunologia , Histamina/toxicidade , Interleucina-5/imunologia , Interleucina-5/metabolismo , Masculino , Camundongos , Microesferas , Ovalbumina/administração & dosagem , Ovalbumina/imunologia , Ovalbumina/toxicidade , Ratos , Proteínas Recombinantes/análise , Proteínas Recombinantes/metabolismo , Contagem de CintilaçãoRESUMO
1. To investigate further the mechanism of the long duration of action of the selective beta 2-adrenoceptor agonist, salmeterol, we have determined the duration of action of some responses to salmeterol which are not mediated through beta 2-adrenoceptors. 2. In the presence of propranolol (1 microM), salmeterol (1-30 microM) caused concentration-related relaxation of superfused, pre-contracted strips of guinea-pig gastric fundus. On washing the tissues, these relaxant responses were rapidly lost, the time to 50% recovery being approximately 30 min. 3. In human neutrophils, salmeterol (1-100 microM) caused concentration-related inhibition of FMLP-induced O2- release. Propranolol (1 microM) had little or no effect on the inhibitory activity of salmeterol. Washing the cells twice over a 40 min period caused a marked reduction of the inhibitory activity of salmeterol. 4. In guinea-pig superfused trachea, in the absence of propranolol, infusions of (RS)-salmeterol (10-30 nM) and the less potent (S)-enantiomer of salmeterol (300-3000 nM) inhibited electrically-induced contractile responses. When the infusion was stopped, there was no recovery from the inhibitory responses within 200 min. In the presence of propranolol (1 microM), infusions of (RS)-salmeterol (10 microM) and (S)-salmeterol (10-100 microM) also inhibited the contractile responses, but, in contrast, on stopping the infusions differences were observed in recovery times. Thus no appreciable recovery was observed from the responses to (RS)-salmeterol, whereas a rapid loss of inhibition was observed on stopping the infusion of (S)-salmeterol, the time to 50% recovery being 30-35 min. 5. These relatively short-lasting effects of salmeterol which are not mediated through beta 2-adrenoceptors, contrast with the persistence of the responses which are mediated through beta 2-adrenoceptors seen in a variety of tissues, but are similar to the rate of dissociation of salmeterol observed from artificial membranes. These observations suggest that the sustained agonist activity of salmeterol is peculiar to responses mediated by beta 2-adrenoceptors.
Assuntos
Albuterol/análogos & derivados , Receptores Adrenérgicos beta 2/fisiologia , Agonistas Adrenérgicos beta/farmacologia , Antagonistas Adrenérgicos beta/farmacologia , Albuterol/farmacologia , Alprenolol/farmacologia , Animais , Estimulação Elétrica , Fundo Gástrico/efeitos dos fármacos , Cobaias , Humanos , Técnicas In Vitro , Masculino , Neutrófilos/efeitos dos fármacos , Neutrófilos/metabolismo , Receptores Adrenérgicos beta 2/efeitos dos fármacos , Xinafoato de Salmeterol , Superóxidos/antagonistas & inibidores , Superóxidos/metabolismo , Traqueia/efeitos dos fármacos , Traqueia/fisiologiaRESUMO
AIMS: The new potent and selective beta 2-adrenoceptor agonist, GR 114297A (picumeterol) is the R-enantiomer of the racemic form, GR 63411B. Picumeterol has been shown to produce long-lasting relaxation of airways smooth muscle both in vitro and in vivo. We assessed the intrinsic activity of picumeterol by increasing intracellular levels of c-AMP and compared this with isoprenaline and salbutamol. METHODS: In human atopic asthmatics, we have investigated the duration of action and efficacy of picumeterol and GR 63411B with regard to improvement in resting lung function (i.e. FEV1) and airways responsiveness (i.e. PC20) to methacholine (MCh). The study design consists of two clinical parts each for one drug. Different asthmatics participated in the two studies, seven in the first part and eight in the second part. In human bronchial smooth muscle cells in vitro, we have investigated the intrinsic activity of picumeterol in increasing intracellular levels of cyclic AMP and compared it with isoprenaline and salbutamol. RESULTS: In vivo, both drugs caused bronchodilatation with similar potency, but, their effects were short-lasting. Despite their bronchodilator activity, neither drug improved PC20, when compared with placebo. In vitro, picumeterol was found have intrinsic activity lower than the other beta 2-adrenoceptor agonists tested. CONCLUSIONS: In the clinical studies, the bronchodilator potencies of picumeterol and GR 63411B were similar. However, both drugs were short-acting, which is at odds with their activity in vitro. Our data suggest that these compounds display dissociation between bronchodilator activity and protection against MCh-induced bronchoconstriction. These findings may be explained by low intrinsic activity and need further conformation.
Assuntos
Agonistas Adrenérgicos beta/uso terapêutico , Piridinas/uso terapêutico , Agonistas de Receptores Adrenérgicos beta 2 , Agonistas Adrenérgicos beta/efeitos adversos , Agonistas Adrenérgicos beta/farmacocinética , Albuterol/farmacologia , Área Sob a Curva , Células Cultivadas , AMP Cíclico/metabolismo , Método Duplo-Cego , Humanos , Técnicas In Vitro , Isoproterenol/farmacologia , Masculino , Músculo Liso/citologia , Músculo Liso/efeitos dos fármacos , Músculo Liso/metabolismo , Piridinas/efeitos adversos , Piridinas/farmacocinética , Testes de Função RespiratóriaRESUMO
Ovalbumin (OvA) inhalation by sensitized guinea-pigs caused a pronounced rise in interleukin (IL)-5 in bronchoalveolar lavage (BAL) fluid at both 3 and 24 h after antigen exposure. The increased levels at 24 h were attenuated by the phosphodiesterase inhibitors Ro 20-1724 and aminophylline and by dexamethasone, all of which also attenuated the concurrent lung eosinophilia. The rise in IL-5 at 3 h was additionally attenuated by the PDE3 inhibitor, siguazodan, which failed to attenuate the eosinophilia at 24 h. These results suggest a pivotal action of these compounds on the later rise in IL-5. Ro 20-1724, aminophylline, siguazodan and dexamethasone attenuated a rise in IL-8 levels in BAL fluid at 3 h and the subsequent neutrophilia at 24 h. There was no increase in plasma ACTH at 3 and 24 h after OvA challenge but cortisol levels were elevated at 3 h. This was inhibited by Ro 20-1724, siguazodan and dexamethasone. Thus, elevation of plasma cortisol does not explain the anti-inflammatory actions of these compounds. Aminophylline, however, did raise plasma cortisol at both 3 and 24 h after antigen challenge which may be an important further mechanism of action for this compound.
Assuntos
Hormônio Adrenocorticotrópico/sangue , Hiper-Reatividade Brônquica/metabolismo , Hidrocortisona/sangue , Interleucina-5/metabolismo , Interleucina-8/metabolismo , Pulmão/efeitos dos fármacos , Inibidores de Fosfodiesterase/farmacologia , 4-(3-Butoxi-4-metoxibenzil)-2-imidazolidinona/farmacologia , Aminofilina/farmacologia , Animais , Anti-Inflamatórios/farmacologia , Líquido da Lavagem Broncoalveolar/química , Líquido da Lavagem Broncoalveolar/citologia , Dexametasona/farmacologia , Eosinófilos , Glucocorticoides/farmacologia , Guanidinas/farmacologia , Cobaias , Pulmão/metabolismo , Macrófagos , Masculino , Neutrófilos , Piridazinas/farmacologiaRESUMO
The four beta 2-adrenoceptor agonists, clenbuterol, bambuterol, formoterol and salmeterol, are all long-acting bronchodilators, that have distinct mechanisms for their extended durations of action. Various theories have been put forward in an attempt to explain these mechanisms. In this respect, there is strong evidence for the existence of specific additional binding sites (exosites) for salmeterol and related compounds, and that exosites exist on non-ligand recognition regions of the beta 2-adrenoceptor protein. Here, Robert Coleman and colleagues compare and contrast the profiles of action of these long-acting beta 2-adrenoceptor agonists, particularly as they relate to the role of exosites.
Assuntos
Agonistas alfa-Adrenérgicos/farmacologia , Agonistas de Receptores Adrenérgicos beta 2 , Broncodilatadores/farmacologia , Animais , HumanosRESUMO
We have assessed the suitability of electrically-stimulated superfused preparations of guinea-pig trachea, cat trachea and human bronchus for investigating the relaxant activity of the beta-adrenoceptor agonist, isoprenaline. Superfused strips of guinea-pig trachea, cat trachea and human bronchus all contracted in response to electrical stimulation. Guinea-pig trachea possesses inherent tone, and in its presence, electrical stimulation caused biphasic responses, comprising a modest, transient contraction, usually followed by a longer lasting relaxation. Human bronchus also possesses inherent tone, but responses were variable, generally monophasic, comprising a transient contraction of variable magnitude, but a longer lasting relaxation was occasionally observed after the transient contraction. Cat trachea possesses no inherent tone, and electrical stimulation of this preparation caused simple monophasic contractile responses. On guinea-pig trachea, addition of indomethacin (2.8 microM) abolished the inherent tone, and under these conditions, electrical stimulation caused monophasic contractile responses similar to those observed in cat trachea. On human bronchus, however, indomethacin enhanced inherent tone, which tended to uncover or exaggerate any relaxant component in the responses to electrical stimulation. The 5-lipoxygenase inhibitor, zileuton (10 microM), reduced, but did not abolish, the tone and converted the electrically-induced response to a monophasic contraction. In all preparations in which inherent tone was low or absent, whether naturally (cat trachea) or through pharmacological intervention (guinea-pig trachea with indomethacin, or human bronchus with zileuton), isoprenaline (1-100 nM) inhibited electrically-stimulated contractions in a concentration-related fashion (EC50s: 9-100 nM). In preparations exhibiting inherent tone (guinea-pig trachea with indomethacin or human bronchus with or without indomethacin), this tone was inhibited by isoprenaline. This relaxant activity, on guinea-pig trachea at least, was concentration-related (EC50: 5.4 nM). Such isoprenaline-induced relaxations complicated the analysis of inhibitory effects against electrically-induced contractions. Thus, in such experiments, only at higher concentrations did isoprenaline reliably inhibit these contractions (EC50: 23-119 nM), lower concentrations of isoprenaline often resulting in an apparent enhancement. The enhancement was probably artefactual, resulting from the fact that the electrically-induced contractions originated from a lower baseline. These data suggest that electrically-stimulated airway preparations are suitable for evaluating the relaxant activity of beta-adrenoceptor agonists, but the relaxant potency should be assessed in preparations lacking inherent tone, such as cat trachea, guinea-pig trachea in the presence of cyclo-oxygenase inhibition, or human bronchus in the presence of 5-lipoxygenase inhibition.
Assuntos
Agonistas de Receptores Adrenérgicos beta 2 , Agonistas Adrenérgicos beta/farmacologia , Brônquios/efeitos dos fármacos , Brônquios/fisiologia , Traqueia/efeitos dos fármacos , Traqueia/fisiologia , Animais , Gatos , Avaliação Pré-Clínica de Medicamentos/métodos , Estimulação Elétrica , Feminino , Cobaias , Humanos , Técnicas In Vitro , Isoproterenol/farmacologia , Masculino , Relaxamento Muscular/efeitos dos fármacosRESUMO
Formoterol, like salbutamol and salmeterol, relaxed isolated preparations of guinea-pig trachea and human bronchus, and inhibited antigen-induced mediator release from human lung fragments in a concentration-related fashion. In each case, these actions were mediated through beta 2-adrenoceptors, with formoterol being 50-120-fold more potent than salbutamol, and 2-27-fold more potent than salmeterol. The duration of action of formoterol was longer than that of salbutamol in all preparations, but was markedly shorter than that of salmeterol, whose actions persisted for many hours despite continuous or extensive washing of the tissues. In conscious guinea-pigs, inhaled formoterol, salbutamol and salmeterol all caused dose-related inhibition of histamine-induced bronchoconstriction. Formoterol was again more potent (10-20-fold) than either salbutamol or salmeterol. However, while the actions of a threshold-effective dose of formoterol persisted for less than 3 h, somewhat longer than those of salbutamol (< 1.5 h), an equivalent dose of salmeterol was active for at least 6 h. Therefore, while formoterol is a potent beta 2-adrenoceptor agonist in vitro and in vivo, and is consistently longer-acting than salbutamol, its duration of action is markedly shorter than that of salmeterol.
Assuntos
Albuterol/análogos & derivados , Albuterol/farmacologia , Brônquios/efeitos dos fármacos , Broncodilatadores/farmacologia , Etanolaminas/farmacologia , Pulmão/citologia , Pulmão/efeitos dos fármacos , Mastócitos/efeitos dos fármacos , Músculo Liso/efeitos dos fármacos , Traqueia/efeitos dos fármacos , Albuterol/farmacocinética , Animais , Células Cultivadas , Dinoprosta/farmacologia , Estimulação Elétrica , Etanolaminas/farmacocinética , Fumarato de Formoterol , Cobaias , Humanos , Técnicas In Vitro , Masculino , Relaxamento Muscular/efeitos dos fármacos , Xinafoato de SalmeterolRESUMO
1. We have investigated the potency and duration of action of isoprenaline and a range of beta-adrenoceptor agonists as relaxants of inherent tone in human superfused, isolated bronchial smooth muscle, a tissue reported to contain a homogeneous population of beta 2-adrenoceptors. 2. All of the beta-adrenoceptor agonists caused concentration-related inhibition of inherent tone, with isoprenaline having an EC50 of 27 nM. The rank order of agonist potency was: formoterol > or = -salmeterol > or = clenbuterol > fenoterol = isoprenaline > terbutaline > or = salbutamol > quinprenaline. 3. Relaxant responses to salmeterol were fully reversed by the selective beta 2-adrenoceptor blocking drug, ICI 118551, demonstrating the involvement of beta 2-adrenoceptors. 4. Rt50, i.e. the time taken for 50% recovery from the effects of an EC50 concentration of agonist, differed considerably between the different beta 2-adrenoceptor agonists. Most agonists were short-acting, having Rt50 values less than 13 min. Quinprenaline was of moderate duration, with an Rt50 value of > or = 20 min. In contrast, salmeterol was extremely long-acting, with no sign of recovery within 4 h. 5. Estimates of relative potency and duration of action were similar to those previously determined for these agonists in the guinea-pig isolated trachea. These results suggest, therefore, that guinea-pig trachea is a suitable alternative to human bronchus for the evaluation of the actions of beta-adrenoceptor agonists on airways smooth muscle.
Assuntos
Agonistas Adrenérgicos beta/farmacologia , Brônquios/efeitos dos fármacos , Músculo Liso/efeitos dos fármacos , Agonistas Adrenérgicos beta/farmacocinética , Humanos , Relaxamento Muscular/efeitos dos fármacos , Fatores de TempoRESUMO
1. This study has explored the mechanism underlying the long duration of action of the beta 2-adrenoceptor agonist, salmeterol. 2. Salmeterol, salbutamol and isoprenaline caused a concentration-related inhibition of electrically-induced contractile responses of the guinea-pig superfused trachea preparation. The effects of both isoprenaline and salbutamol were rapid in onset and rapidly reversed upon removal of the agonist. In contrast, the effects of salmeterol were slower in onset and could not be reversed by superfusion of the tissue with agonist-free Krebs solution even for periods of up to 10 h. 3. The effects of salmeterol were, however, readily reversed by a number of beta-adrenoceptor blocking drugs, as was the effect of a continuous infusion of isoprenaline. Upon removal of the antagonist, however, the effects of salmeterol and of the isoprenaline infusion were reasserted at a rate which was inversely related to the lipophilicity of a beta-adrenoceptor blocking drugs. 4. Salmeterol inhibited the binding of [125I]-(-)-iodopindolol (100 pM) to rat lung membranes (pIC50 7.1), with isoprenaline (pIC50 6.2) and salbutamol (pIC50 5.1) having lower potencies. The inhibition of binding by salmeterol was apparently non-competitive, whereas that produced by salbutamol and isoprenaline was competitive in nature. 5. Isoprenaline and salbutamol rapidly dissociated from their binding sites, whereas in marked contrast, the binding of salmeterol showed no dissociation for periods of up to 1 h. 6. These data are consistent with the mechanism in which salmeterol binds adjacent to the active site of the beta 2-adrenoceptor, such that the drug cannot be washed out of the tissue, yet can interact with and activate the receptor. This latter property is susceptible to antagonism by beta-adrenoceptor blocking drugs but is reassured when the antagonists are removed.
Assuntos
Agonistas Adrenérgicos beta/farmacologia , Antagonistas Adrenérgicos beta/farmacologia , Albuterol/análogos & derivados , Pulmão/efeitos dos fármacos , Albuterol/farmacologia , Animais , Estimulação Elétrica , Cobaias , Técnicas In Vitro , Isoproterenol/farmacologia , Masculino , Relaxamento Muscular/efeitos dos fármacos , Músculo Liso/efeitos dos fármacos , Perfusão , Ensaio Radioligante , Ratos , Xinafoato de Salmeterol , Sotalol/farmacologia , Fatores de TempoRESUMO
Salmeterol was developed to provide prolonged bronchodilatation to control nocturnal symptoms and improve maintenance therapy in asthmatic patients. Salmeterol is > 10,000 times more lipophilic than salbutamol and has greater affinity for the beta 2-adrenoceptor. Membrane binding is non-competitive and dissociation is slow so that its effects last for many hours. Despite this, salmeterol does not accumulate in tissues. Its mechanism of action can be explained by binding to a specific exo-site domain of the beta 2-receptor protein to produce continuous stimulation of the active site of the receptor, which gives salmeterol a profile of pharmacological activity unlike that of other beta 2-agonists. Due to its potent and prolonged activation of beta 2-adrenoceptors in airway smooth muscle cells, endothelial cells, mast cells and epithelial cells, salmeterol induces prolonged bronchodilatation, reduced vascular permeability, inhibition of inflammatory mediators, stimulation of ciliary function and modulation of ion and water transport across the bronchial mucosa.
Assuntos
Agonistas Adrenérgicos beta/farmacologia , Albuterol/análogos & derivados , Broncodilatadores/farmacologia , Albuterol/farmacologia , Animais , Humanos , Xinafoato de SalmeterolRESUMO
1. Salmeterol, a novel, long-acting beta-adrenoceptor agonist, has been compared with isoprenaline and salbutamol for activity in vitro on a range of beta-adrenoceptor containing preparations from laboratory animals and man, and in vivo for bronchodilator activity in the conscious guinea-pig. 2. Salmeterol, like isoprenaline and salbutamol, relaxed preparations of both guinea-pig trachea (contracted by prostaglandin (PG)F2alpha or electrical stimulation) and human bronchus (contracted by PGF 2 alpha) in a concentration-related fashion. Salmeterol was of similar potency to isoprenaline and more potent than salbutamol on both airway preparations. 3. Relaxant responses of superfused guinea-pig trachea and human bronchus to isoprenaline and salbutamol declined rapidly when the agonists were washed from the tissues, with complete recovery within 10 min, whereas responses to salmeterol were more persistent. In electrically-stimulated guinea-pig trachea preparations, inhibition by salmeterol persisted for periods of up to 12h, despite continuous superfusion with agonist-free medium. However, these persistent responses were rapidly and fully reversed by the beta-adrenoceptor blocking drug, propranolol (0.1 microM). In further studies on guinea-pig trachea, propranolol caused concentration-related parallel, rightward shifts of salmeterol concentration-effect curves, yielding a pA2 of 9.0. The slope of the Schild plot was 1.02. 4. Another beta-adrenoceptor blocking drug, sotalol (10 microM), also fully and rapidly reversed established submaximal responses to salmeterol in superfused guinea-pig trachea. However, after administration of sotalol was stopped, the antagonism waned, and salmeterol responses were reasserted without the addition of further agonist. 5. In the beta 1-adrenoceptor containing preparation, rat left atria, isoprenaline exhibited potent, concentration-related, positive inotropic activity, whereas salbutamol and salmeterol were at least 2000-5000 fold less potent, and appeared to be partial agonists. At a concentration of 72 microM, salmeterol exhibited weak antagonism of isoprenaline-induced increases in atrial force of contraction. This antagonism was less marked than that caused by salbutamol (42 microM).6. On the guinea-pig isolated gastric fundus strip, a putative beta3-adrenoceptor containing preparation, salbutamol and salmeterol had only modest agonist activity, being 20-30 fold less potent than isoprenaline and the selective ,beta3-adrenoceptor agonist, BRL 35135.7. In conscious guinea-pigs, inhaled salmeterol and salbutamol were approximately equipotent in causing dose-related bronchodilatation. Whereas the duration of action of salbutamol at its threshold-effective dose was less than 90min, the responses to a similarly effective dose of salmeterol were well-maintained for at least 6 h.8. Salmeterol is therefore a potent and selective beta2-adrenoceptor agonist with a remarkably long duration of action in isolated superfused airways smooth muscle. It also causes persistent bronchodilatation in vivo, in the guinea-pig, when administered by the inhaled route.
Assuntos
Agonistas Adrenérgicos beta/farmacologia , Albuterol/análogos & derivados , Albuterol/antagonistas & inibidores , Albuterol/farmacologia , Animais , Broncodilatadores/farmacologia , Dinoprosta/farmacologia , Estimulação Elétrica , Cobaias , Humanos , Técnicas In Vitro , Isoproterenol/farmacologia , Masculino , Relaxamento Muscular/efeitos dos fármacos , Músculo Liso/efeitos dos fármacos , Músculo Liso/fisiologia , Propranolol/farmacologia , Ratos , Xinafoato de Salmeterol , Estômago/efeitos dos fármacos , Estômago/fisiologia , Traqueia/efeitos dos fármacos , Traqueia/fisiologiaRESUMO
We have developed a novel, eight-chamber superfusion system that is suitable for a variety of applications involving the study of both contraction and relaxation of smooth muscle preparations, and the effect of agents that interfere with these actions. The system allows electrical stimulation of preparations, and thus neuronally mediated responses and agents that interfere with neurotransmission may also be studied. To demonstrate some of the applications of the system, we have evaluated both spasmogenic and spasmolytic agents on the guinea-pig isolated tracheal strip preparation. The potency and the times for onset and offset of action of the spasmogens, acetylcholine, histamine, and prostaglandin F2 alpha, and the spasmolytics, isoprenaline, clenbuterol, salbutamol, papaverine, N-ethylcarboxamide adenosine, theophylline, and verapamil, have been investigated. The spasmolytic agents have been tested against both prostaglandin F2 alpha-induced tone and electrically induced contractile responses of the guinea-pig trachea. This superfusion system has several advantages over previously described superfusion or immersion techniques. It is compact and allows simultaneous study of up to eight preparations. It is suitable for a wide range of tissues, and the use of this system avoids the necessity of repeatedly washing drugs from organ baths. However, one of the most important applications of the system is its use in the study of rates of onset and offset of drug action. We believe, therefore, that this system represents an important alternative to the classical organ bath for in vitro pharmacological experimentation.
Assuntos
Contração Muscular/efeitos dos fármacos , Músculo Liso/fisiologia , Parassimpatolíticos/farmacologia , Traqueia/fisiologia , Acetilcolina/farmacologia , Animais , Dinoprosta/farmacologia , Avaliação Pré-Clínica de Medicamentos/métodos , Estimulação Elétrica , Cobaias , Histamina/farmacologia , Técnicas In Vitro , Masculino , Músculo Liso/efeitos dos fármacos , Perfusão/métodos , Traqueia/efeitos dos fármacosRESUMO
The inhibitory effects of a range of natural and synthetic derivatives of adenosine on the antigen-induced release of histamine and slow reacting substance of anaphylaxis (SRS-A) from human lung has been studied. The nucleotides ATP, ADP and AMP appear to act by being converted to adenosine. The rank order of inhibitory potency of the synthetic analogues indicates that these compounds act at an extracellular A2/Ra purinoceptor. The xanthines, 1, 3-diethyl-8-phenylxanthine, 8-phenyltheophylline and theophylline antagonized the inhibitory action of N-ethyl-carboxamideadenosine competitively. Theobromine was inactive. This supports the view that the inhibitory receptor is of the A/R type. Hexobendine and dipyridamole, reported to antagonize the uptake of adenosine, failed to modify the response of human lung fragments to adenosine. The P site agonist 2',5' dideoxyadenosine inhibited the release of histamine and SRS-A. This effect was not prevented by the inhibitors of uptake, hexobendine and dipyridamole, nor was it antagonized by 8-phenyltheophylline.
Assuntos
Didesoxiadenosina/análogos & derivados , Liberação de Histamina/efeitos dos fármacos , Pulmão/metabolismo , Receptores de Superfície Celular/análise , SRS-A/metabolismo , Adenosina/análogos & derivados , Adenosina/farmacologia , Adenosina-5'-(N-etilcarboxamida) , Animais , Desoxiadenosinas/análogos & derivados , Desoxiadenosinas/farmacologia , Dipiridamol/farmacologia , Cobaias , Hexobendina/farmacologia , Humanos , Técnicas In Vitro , Receptores Purinérgicos , Teofilina/análogos & derivados , Teofilina/farmacologia , Fatores de TempoRESUMO
The release of histamine from rat peritoneal mast cells induced by alpha-chymotrypsin and that induced by antigen have characteristics in common. The kinetics of histamine release initiated by the two agents are similar. Both alpha-chymotrypsin and antigen release histamine in the absence of extracellular calcium, phosphatidyl serine enhances the release, and disodium cromoglycate inhibits both reactions. In contrast, extracellular alpha-chymotrypsin does not induce histamine release from cells isolated from fragments of human lung, human basophils, histamine-containing cells lavaged from the bronchial lumen of the rhesus monkey, fragments of human lung and fragments of guinea pig lung.